At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Laboratory Biomarker Analysis for Acute Biphenotypic Leukemia and 4 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Pharmacyclics LLC.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionApr 2021
TodayJul 2026
First PostedAug 30, 2017
Enrollment StartSep 12, 2017
Primary CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.8 years ago
Interventions
Ibrutinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies